Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
BDKRB1 623 CHEMBL2370700 CHEMBL2370700 antagonist GuideToPharmacologyInteractions
BDKRB1 623 KETOROLAC CHEMBL469 antagonist GuideToPharmacologyInteractions
BDKRB1 623 MK0686 CHEMBL232943 antagonist ChemblInteractions
BDKRB1 623 KETOPROFEN CHEMBL571 agonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL408846 CHEMBL408846 antagonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL80472 CHEMBL80472 antagonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL2311192 CHEMBL2311192 antagonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL273869 CHEMBL273869 antagonist GuideToPharmacologyInteractions
BDKRB1 623 MEFLOQUINE CHEMBL416956 antagonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL2018875 CHEMBL2018875 antagonist GuideToPharmacologyInteractions
BDKRB1 623 BI113823 CHEMBL3545386 antagonist ChemblInteractions
BDKRB1 623 CHEMBL416340 CHEMBL416340 agonist GuideToPharmacologyInteractions
BDKRB1 623 CHEMBL415848 CHEMBL415848 antagonist GuideToPharmacologyInteractions
BDKRB1 623 ICATIBANT CHEMBL2028850 antagonist GuideToPharmacologyInteractions
BDKRB1 623 BRADYKININ CHEMBL406291 agonist GuideToPharmacologyInteractions
BDKRB1 623 DIMETHYLALLYL DIPHOSPHATE CHEMBL343480 agonist GuideToPharmacologyInteractions
BDKRB1 623 Safotibant CHEMBL1254771 antagonist ChemblInteractions

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
BDKRB1 rs12050217 AA + AG perindopril efficacy yes Three SNPS are combined for a risk score ranging between 0 and 6: rs275651, rs5182, and rs12050217. Patients with risk scores of 0 and 1 and treated with perindopril had absolute risk reductions of 7.50% (95% CI: 3.69-11.73) and 4.30% (95% CI: 2.00-6.53), respectively. Nonsignificant estimated absolute risk increase of 1.32% was observed in patients with a PGXscore >=3. Lower risk score had better response to treatment by primary endpoint of cardiovascular mortality, nonfatal MI, and resuscitated cardiac arrest. Part of PERGENE trial for cardiovascular outcomes. Genotypes AA + AG is associated with decreased response to perindopril in people with Coronary Artery Disease as compared to genotype GG. 27021566 1447964483